<Suppliers Price>

DMAPT

Names

[ CAS No. ]:
870677-05-7

[ Name ]:
DMAPT

Biological Activity

[Description]:

DMAPT (Dimethylamino Parthenolide), a water soluble analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].

[Related Catalog]:

Research Areas >> Cancer

[Target]

NF-κB[1].


[In Vitro]

DMAPT treatment decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells[2]. Treatment of PC-3 and DU145 cells with 5 and 4 μM DMAPT, respectively, increases the population doubling times of PC-3 prostate cancer cells from 23.0 ± 5.0 h to 42.0 ± 3.0 h and of the DU145 cells from 20.4 ± 2.2 h to 72.5 ± 24.8 h[2]. Cell Proliferation Assay[2] Cell Line: PC-3 and DU145 cells. Concentration: PC-3 cells (0, 2.5, 5 μM), DU145 cells (0 and 4 μM). Incubation Time: 24 and 48 hours. Result: Decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells.

[In Vivo]

Treatment with DMAPT (100 mg/kg, Oral gavage daily for 7 days) increases sensitivity of PC-3 tumor xenografts to X-rays[2]. DMAPT (100 mg/kg, Oral gavage thrice weekly from 42 to 300 days since birth) treatment slows normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%[3]. DMAPT further reduces the metastatic area below that of the water vehicle treatment group in lung tissues (0.10% ± 0.15 SD, 92% reduction, p = 0.0028) in TRAMP mice[3]. Animal Model: PC-3 tumor xenograft in athymic nude mice[2]. Dosage: 100 mg/kg. Administration: Oral gavage daily for 7 days. Result: Increased sensitivity of PC-3 tumor xenografts to X-rays. Animal Model: Six-week-old male TRAMP mice[3]. Dosage: 100 mg/kg. Administration: Oral gavage thrice weekly from 42 to 300 days since birth. Result: Slowed normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.

[References]

[1]. Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009 Aug 1;19(15):4346-9.

[2]. Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326.

[3]. Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35(7):649-661.

Chemical & Physical Properties

[ Molecular Formula ]:
C17H27NO3

[ Molecular Weight ]:
293.40


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.